Roivant Sciences (ROIV) Total Liabilities (2020 - 2026)

Roivant Sciences (ROIV) has reported Total Liabilities for 7 consecutive years, with $384.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 77.49% year-over-year to $384.6 million; the trailing twelve-month figure through Jun 2026 stood at $384.6 million (up 77.49% YoY), and the FY2026 full-year result was $416.3 million, up 66.68% from the prior year.
• Total Liabilities slipped to $384.6 million in Q2 2026 per ROIV's latest filing, from $416.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $822.5 million in Q2 2022 and bottomed at $216.7 million in Q2 2025.
• Historically, Total Liabilities has averaged $550.5 million across 5 years, with a median of $613.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities sank 67.73% in 2025, then surged 77.49% in 2026.
• Over 5 years, Total Liabilities stood at $775.8 million in 2022, then dropped by 6.15% to $728.1 million in 2023, then tumbled by 64.79% to $256.4 million in 2024, then retreated by 2.04% to $251.1 million in 2025, then soared by 53.15% to $384.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $384.6 million, $416.3 million, and $251.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.